Devonian Health Group, Inc. (TSE:GSD) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Devonian Health Group reported a significant 360% increase in first-quarter revenues, boosted by the success of its Altius subsidiary’s pharmaceutical product, DEXLANSOPRAZOLE. Despite the revenue surge, the company posted a net loss of $0.002 per share. Additionally, Devonian granted over 1.5 million stock options to its independent directors, signaling confidence in future growth.
For further insights into TSE:GSD stock, check out TipRanks’ Stock Analysis page.
